Novartis Buys Breast Cancer Drug for $2B in Upfront Deal | STAT+

Novartis is acquiring Synnovation Therapeutics, a Delaware-based biotechnology company, for $2 billion upfront, with potential for another $1 billion contingent on future milestones. The deal centers around SNV4818, an experimental oral medication currently undergoing a Phase 1/2 clinical trial for HR-positive, HER2-negative breast cancer. This acquisition signals a significant move by Novartis to bolster its oncology pipeline with a potentially targeted therapy.

Targeting PI3Kα Mutations in Breast Cancer

SNV4818 is designed to inhibit the PI3Kα enzyme, a protein often mutated in various cancers, including breast cancer. What sets this drug apart is its selectivity. It aims to target mutated forms of PI3Kα while largely sparing the normal, healthy version of the protein. This precision is crucial, as earlier PI3K inhibitors faced limitations due to their impact on both mutated and wild-type PI3Kα, leading to significant side effects. Synnovation Therapeutics highlights that SNV4818 may effectively address a range of PI3Kα mutations, including those in the kinase (H) and helical (E) domains.

HR-positive, HER2-negative breast cancer is a common subtype, accounting for a substantial proportion of breast cancer diagnoses. The “HR” designation refers to hormone receptor positivity (estrogen and/or progesterone receptors), while “HER2-negative” indicates the absence of amplification of the HER2 gene. These characteristics influence treatment strategies, and the development of new therapies targeting specific molecular pathways within this subtype is a critical area of research.

Phase 1/2 Trial and Clinical Development

The ongoing Phase 1/2 trial, led by Dr. Timothy Yap at the University of Texas MD Anderson Cancer Center, is evaluating both the safety and preliminary efficacy of SNV4818. The trial has a two-pronged approach: assessing the drug as a standalone therapy (monotherapy) in patients with solid tumors harboring PI3Kα activating mutations, and evaluating its combination with fulvestrant in patients with advanced HR+/HER2- breast cancer. Fulvestrant is a selective estrogen receptor degrader, commonly used in the treatment of hormone receptor-positive breast cancer. Synapse details that the trial began in February 2025.

Phase 1 trials primarily focus on safety and determining the appropriate dosage. Phase 2 trials then begin to assess efficacy, looking for signs that the drug is having a positive impact on the disease. The combination of SNV4818 with fulvestrant is designed to potentially enhance treatment effectiveness by targeting multiple pathways involved in cancer growth and progression.

The PI3K Pathway and Targeted Therapies

The PI3K pathway is a crucial signaling network within cells that regulates growth, proliferation, and survival. Mutations in genes encoding components of this pathway, such as PIK3CA (which encodes the PI3Kα enzyme), are frequently observed in various cancers. These mutations can lead to overactivation of the pathway, driving uncontrolled cell growth.

Targeted therapies aim to specifically disrupt these aberrant signaling pathways, offering a more precise approach to cancer treatment compared to traditional chemotherapy, which often affects both cancerous and healthy cells. However, the development of effective PI3K inhibitors has been challenging. Earlier generations of these drugs often lacked the selectivity needed to avoid significant side effects, limiting their clinical utility. SNV4818’s potential to selectively target mutated PI3Kα represents a step forward in this area.

Synnovation’s Pipeline and Novartis’s Strategy

This acquisition marks the second program from Synnovation Therapeutics to enter clinical trials. Their lead candidate, SNV1521, a PARP1 selective inhibitor, began a Phase 1 trial in January 2024. PARP1 inhibitors are a class of drugs used to treat cancers with defects in DNA repair mechanisms. Business Wire reported on the initial dosing of SNV4818 in February 2025.

For Novartis, this acquisition aligns with a broader strategy of strengthening its oncology portfolio through targeted therapies and innovative drug candidates. The company has been actively investing in precision medicine approaches, aiming to develop treatments tailored to the specific genetic and molecular characteristics of individual patients’ cancers. This approach holds the promise of improving treatment outcomes and minimizing side effects.

What’s Next for SNV4818?

The immediate focus will be on continuing the Phase 1/2 clinical trial to gather more data on the safety, tolerability, and preliminary efficacy of SNV4818. Researchers will be closely monitoring patients for any adverse events and assessing the drug’s impact on tumor growth. If the initial results are promising, Novartis will likely move forward with larger, more definitive Phase 3 trials to confirm the drug’s effectiveness and seek regulatory approval. The timeline for potential approval will depend on the outcome of these trials and the review process by regulatory agencies like the FDA in the United States and the EMA in Europe. Further research will also be needed to identify biomarkers that can predict which patients are most likely to benefit from SNV4818, further refining the precision of this targeted therapy.